• 약학회지
• /
• 제36권2호
• /
• pp.140-149
• /
• 1992

Anti-allergic action of each water extracts of some crude drugs was investigated in mice and rats. The activity of hyaluronidase which was used in the screening test of anti-allergic action was inhibited significantly by Amomi Semen, Asiasari Radix, Cimicifugae Rhizoma, Cinnamomi Ramulus, Glycyrrhizae Radix and Scutellariae Radix. The 48-hour homologous passive cutaneous anaphylaxis(48-hr PCA) in mouse ear was inhibited significantly by intraperitoneal(i.p.) injection of Amomi Semen, Cimicifugae Rhizoma, and ketotifen, a comparative drug of an anti-allergic action. The increase of vascular permeability induced by histamine or serotonin was inhibited significantly by i.p. injection of Amomi Semen, Cimicifugae Rhizoma, Cinnamomi Ramulus and ketotifen. In rat dorsal skin, the increase of vascular permeability which was induced by histamine, serotonin or compound 48/80 was inhibited significantly by i.p. injection of Amomi Semen, Asiasari Radix, Cimicifugae Rhizoma, Scutellariae Radix and ketotifen. Armeniacae Semen and Liriopis Tuber which had not inhibited hyaluronidase activity did not inhibit 48-hr PCA and the increase of histamine, serotonin or compound 48/80-induced vascular permeability in mice and rats. These results suggest that each water extract of Amomi Semen and Cimicifugae Rhizoma has anti-allergic action.

• Biomolecules & Therapeutics
• /
• 제2권2호
• /
• pp.149-154
• /
• 1994

Anti-allergic and anti-inflammatory actions of the water extract from Cimicifuga heracleifolia were evaluated in mice and rats. Several criteria were employed to assess the anti-allergic and anti-inflammatory actions of Cimicifuga heracleifolia, such as hyaluronidase activity, mediators-induced vascular permeability changes, 48 hour homologous passive cutaneous anaphylaxis (PCA) histamine release from mast cells, and the carrageenan-induced rat paw edema. To further characterize the active components, the water extract was either extracted with organic solvent or fractionated according to molecular weight, and each fraction was tested for some of anti-allergic parameters. Hyaluronidase activities, both in activating and in activated states, were significantly inhibited by the water extract of Cimicifuga heracleifolia and by some of its subfractions, molecular weight less than 1,000. The water extracts (50~400 mg/kg) significantly inhibited 48 hr homologous PCA and vascular permeability changes induced by chemical mediators (histamine, serotonin, and leukotriene $C_4$) in mice. In the case of histamine-induced vascular permeability changes, more extensive studies were conducted; water extract was either fractionated according to molecular weight or extracted with butanol. Anti-histamine actions were observed only from the water layer, and these active components were of the molecular weight less than 1,000. These anti-allergic actions were observed mainly from mice than from rats. On the other hand, anti-inflammatory actions of the water extract from Cimicifuga heracleifolia were significant in rats.

• Biomolecules & Therapeutics
• /
• 제2권4호
• /
• pp.331-335
• /
• 1994

As a part of the safety evaluation of Pseudomonas vaccine(CFC-101), antigenicity tests were carried out in guinea pigs and mice. In active systemic anaphylaxis(ASA) test, guinea pigs showed no sign or only moderate sign(1/5) when sensitized and challenged with up to 200 $\mu\textrm{g}$/kg. In homologous passive cutaneous anaphylaxis(PCA) test using guinea pigs, inoculation of CFC-101 alone did not produce CFC-101-specific antibody. When inoculated with 200 $\mu\textrm{g}$/kg plus adjuvant, challenge of 200 $\mu\textrm{g}$/kg produced PCA titer of 32(5/5) but challenge of 20 $\mu\textrm{g}$/kg did not produce CFC-101-specific antibody. In heterologous PCA test using mice, CFC-101-specific antibody was not detected when sensitized with CFC-101 alone. Some animals(3/12) showed positive PCA response when inoculated with 200 $\mu\textrm{g}$/kg plus alum. In passive hemagglutination (PHA) test, although no antibody was detected at 20 $\mu\textrm{g}$/kg, inoculation of 200 $\mu\textrm{g}$/kg alone or with alum produced positive response in all animals. This result has already been predicted because CFC-101 is a vaccine developed for the purpose of immunization. From the above results, it can be concluded that there is no adverse antigenic potential up to 10 times clinical dose of 200 $\mu\textrm{g}$/kg.

• 한국축산식품학회지
• /
• 제20권2호
• /
• pp.114-124
• /
• 2000

In this research the results showed that Evans blue stain causes vascular permeation at antibody injection site by the passive cutaneous anaphylaxis(PCA) screening of octpus minor so we concluded. Octopus minor causes allergy. Psedosciaena Polyactis, Raja Kenojei, Metapenaeus joyneri also showed allergenicity. Microwave and autoclaving appeared to reduced allergenicity(up to 99%) during the technological treatment processing. On the other hand, UV light didn't seem to change the protein structure of allergens affect the allergenicity. Therefore, the technological treatment processing of fish such as canning and microwave would possibly reduce the allergenicity. Among the ultrafiltration fraction of Octopus minor, Pseudosciaena Polyactis, Raja Kenojei and Metapenaeus joyneri, those fraction over 100,000 contained allergen and those under 100,000 and when screening allergenic fish went through 10,000∼100,000 ultrafiltration, only the fraction of over 100,000 showed the anaphylactis activity for PCA. However whether screening fish would cause anaphylaxis in human or not is questionable. The future clinical experiment will verify this result with clinical experiment patients. 본 연구 결과로 낙지의 PCA검색으로써 항체주사 부위에 Evan's Blue 착색으로 인하여 vascular permation이 일어나 allergynicity 반응이 인정되므로 낙지는 allergy가 있다고 할 수 있다. 조기, 홍어, 새우도 역시 allergenicity성이 나타난 것을 볼 수 있었다. 또한 공정 중 microwave와 autoclaving은 4가지 수산식품 낙지, 조기, 홍어, 새우의 allergenicity를 현저히 감소시키는 것으로 나타났다. 반면에 자외선은 단백질로 구성된 allergen의 구조는 크게 변화시키지 못하는 것으로 보여진 것을 알 수 있다. 그러므로 생선의 가공방법은 통조림 가공이나 microwave 처리가 allergenicity성을 감소시킬 수 있는 것으로 보여진다. 낙지, 조기, 홍어, 새우의 한외여과 fraction중 고분자인 100,000이상에서만 allergenicity가 나타났다. 따라서 이 allergen들의 분자량은 100,000 이상으로 추정되며 검색된 allergynicity 생선을 10,000∼100,000으로 한외여과 하였을 때 100,000 이상의 fraction에서만 PCA에 의해 allergenicity가 있는 것으로 인정되었다. 그러나 이 검색된 생선이 anaphylaxis가 인간에게서까지도 반응할지는 의문이다. 이 연구의 결과는 차후 임상실험환자에 의하여 최종 검증되어야 한다.

• Toxicological Research
• /
• 제13권1_2호
• /
• pp.153-156
• /
• 1997

The antigenicity of EPO (erythropoietin) was investigated in guinea pig, mice and rats. Antigenicity tests-active systemic anaphylaxis (ASA), passive cutaneous anaphylaxis (PCA) of this materials were performed according to the established Regulation of Korean National Institute of Safety Research (1996, 4, 16). The results were followed: 1. After sensitizaion with EPO emulsified with complete Freund's adjuvant (CFA), guinea pigs didn't show any anaphylatic shock symptom in the ASA test 2. After sensitization with antisera of EPO sensitized mice, blue spots were observed on the hypodermis of back of rats in the PCA test, but diameter of each spot was smaller than 5 mm. From the results of this investigation, the antigenicity of EPO was negative under the present experimental condition.

• Toxicological Research
• /
• 제9권1호
• /
• pp.125-132
• /
• 1993

Antigenic potential of recombinant human growth hormone (LBD-007), a newly developed drug for growth hormone deficiency, was investigated in mice and guinea pigs. 1. Mice showed production of antibodies against LBD-009 (1.5IU/kg) with aluminum hydroxide gel(alum) as an adjuvant, Judaged by the heterologous anaphylaxis (PCA) test using rats. On the other hand, antibodies against ovalbumin (OVA) inoculated with alum were definitely detected. 2. In the studies with guinea pigs, both the inoculation of LBD-009 (0.15IU/kg-1.5IU/kg) only and of LBD-009 with complete Freund's adjuvant (CFA) as an adjuvant did produce weak positive reactions in homologous passive cutaneous anaphylaxis (PCA). On the other hand, the inoculation of ovalbumin with complete Freund's adjuvant (CFA) produced positive reaction in PCA.

• 생명과학회지
• /
• 제18권4호
• /
• pp.494-502
• /
• 2008

본 연구에서는 H. pylori의 감염을 예방하고 치료보조제로 사용할 목적으로 포유동물을 통한 피동면역용 항체를 생산하고자 하였다. 따라서 anti-H. pylori 항체를 함유한 면역우유 생산용 백신개발에 기초자료를 얻고자 H. pylori의 면역성과 면역독성에 관한 실험을 수행하였다. 백신을 반복해서 투여했을 때 야기될 수 있는 알레르기 및 과민반응을 예측하고, 페니실린 쇼크와 같은 심각한 부작용 및 독성유발 가능성을 검색하기 위하여 백신의 면역독성을 평가하였다. 전신성 anaphylaxis 쇼크반응의 유무를 평가하기 위해 각 군당 5마리의 guinea pig에 감작투여한 후 최종감작 1주와 2주째에 귀정맥(ear vein)으로 야기항원을 투여하였다. anaphylaxis 쇼크 반응 시험에서 5마리 중 1마리가 양성반응을 나타낸 경우 의약품의 안전성 평가라는 관점에서는 양성으로 판정한다[11]. H. pylori의 WC항원에 대한 1차 및 2차 야기항원 투여 후 전신성 anaphylaxis 쇼크반응에 대한 관찰 결과는 다음과 같다. H. pylori의 WC에 대한 anaphylaxis 쇼크반응은 WC (H) $60\;{\mu}g/100\;{\mu}l$의 항원농도에서 1차, 2차 야기항원 투여 모두 경증의 증상을 나타내었고, WC (L) $20\;{\mu}g/100\;{\mu}l$의 항원농도에서는 아무런 anaphylaxis 쇼크 증상이 관찰되지 않았다. 그리고 crude urease에 대한 anaphylaxis 쇼크반응은 항원농도가 $20\;{\mu}g/100\;{\mu}l$의 urease (L)와 $60\;{\mu}g/100\;{\mu}l$의 urease (H) 모두에서 아무런 증상도 관찰되지 않았다. Guinea pig-rat를 이용한 PCA 시험에서는 WC (H), WC (L), urease (H), urease (L) 투여군 모두에서 양성반응이 나타나지 않았다. 피부감작성 시험에서는 항원농도에 따라 각각 $80\;{\mu}g/100\;{\mu}l$, $40\;{\mu}g/100\;{\mu}l$, $20\;{\mu}g/100\;{\mu}l$, $20\;{\mu}g/100\;{\mu}l$ 일 때 피부이상 증상 즉, 피부 트러블이 발생하지 않는 최고의 항원농도는 $40\;{\mu}g/100\;{\mu}l$인 것으로 관찰되었다. 결론적으로 항원성 시험에서 H. pylori로부터 분리된 urease 항원이 WC 항원보다 면역독성 측면에서 좀 더 안전할 것으로 조사되었다.

• Toxicological Research
• /
• 제14권2호
• /
• pp.205-209
• /
• 1998

To evaluate immunotoxicity of skin decontamination kit(SDK) newly-developed in Agency for Defense Development(ADD), delayed contact hypersensitivity (maximization) test and passive cutaneous anaphylaxis(PCA) test of SDK were performed and the results were compared with those of M 291. In maximization test, sensitization reaction was induced by id injection (2.5 mg / 0.1 $\textrm{m}{\ell}$/ guinea pig or 2.5 mg+CFA/0.1 $\textrm{m}{\ell}$/guinea pig) and topical application (2.5 mg/$\textrm{m}{\ell}$/guinea pig) with SDK or M291 at an interval of 1 week, and 2 weeks later, challenged by topical application with 25 mg/$\textrm{m}{\ell}$/guinea pig. SDK and M291 did not induce any reactions, showing 0 point of sensitization score and 0% of sensitization rate. In conclusion, it is suggested that SDK and M291 do not induce delayed contact hypersensitivity. In PCA test, rats were administered id with mouse anti-SDK serum and challenged iv with a mixture of antigen SDK and Evan's blue. SDK did not induce blue spots at the injection sites of both high (2.5 mg/mouse) and low (1.25 mg/mouse) dose-induced antisera. In contrast, BSA, positive control produced spots larger than 5 mm in diameter at the injection sites of BSA-induced antiserum up to $2^2$ ~ $2^4$dilution. In conclusion, it is suggested that SDK do not induce IgE production and is not a PCA-reaction inducer.

• Biomolecules & Therapeutics
• /
• 제6권2호
• /
• pp.165-170
• /
• 1998

Antigenic potential of DW-116, a newly synthesized fluoroquinolone, was examined by conduc-ting active systemic anaphylaxis (ASA), passive cutaneous anaphylaxis (PCA) and passive hemagglutination (PHA) tests. In ASA test, mild to moderate signs of anaphylactic responses were observed in the groups sensitized with low (2 mg/body) and high (10 mg/body) doses of DW-116 alone and the group sensitized with DW-116 plus adjuvant. Some moderate to severe anaphylactic reactions were observed in the group sensitized with a DW-116-bovine serum albumin (BSA) conjugate plus adjuvant when challenged with a DW-116-guinea pig senHn albumin (GSA) conjugate. However these reactions were considered to be a cross-reaction between BSA and GSA since similar reactions were induced when challenged by GSA alone. In heterologous PCA test using mice and rats, positive responses were not detected in any of the experimental groups. In PHA test, positive responses were observed in the groups sensitized with low and high doses of DW-116 alone and the group sensitized with DW-116 plus adjuvant. However, these responses were not considered to be drug-specific because some positive responses were also seen in the negative control group. From these results, it was concluded that DW-116 is not likely to have specific antigenic potential in clinical use.

• 동의생리병리학회지
• /
• 제20권1호
• /
• pp.196-201
• /
• 2006

Electroacupuncture(EA) is commonly used in various diseases. In the present study, the effect of EA in the allergic mouse model was examined. Allergy is generated via immunological mechanism and non-immunological mechanism. Mast cells activated dy those mechanisms get to release various substances such as histamine, leukotrienes, prostaglandin, TNF-$\alpha$, IL-4, IL-6, etc. which induce allergic reactions and the following inflammatory responses. To evaluate the anti-allergic effects of EA, mortality, ear swelling response, vascular permeability and cytokine secretion were investigated in EA group and non-EA group of which mice were compound 48/80-induced allergy model or PCA model. Compound 48/80 induces allergic reaction via non-immunological mechanism and PCA model is generated through the same mechanism with immediate-type(Type1) allergic reaction, one of immunological allergic reactions. EA inhibited compound 48/80-induced ear swelling response but did not inhibit the systemic anaphylaxis. EA also inhibited passive cutaneous anaphylaxis(PCA) activated dy anti-dinitrophenol IgE. In addition, EA inhibited IL-6 and TNF-$\alpha$ secretion from 48 h PCA in mice. These results indicate that EA may be used for the treatment of mast cell-mediated allergic diseases, especially immediate-type(Type 1) allergy and non-immunologically mediated allergy.